Streptococcus

Streptococcus
Name	Streptococcus
Domain	Bacteria
Phylum	Bacillota
Class	Bacilli
Order	Lactobacillales
Family	Streptococcaceae
Genus	Streptococcus
Genus authority	Rosenbach 1884
Type species	Streptococcus pyogenes

Streptococcus. This genus of spherical, gram-positive bacteria is a significant component of the human microbiota but also includes major pathogens responsible for a wide spectrum of diseases. Streptococci are classified based on their hemolytic properties on blood agar and serological grouping of cell wall carbohydrates. Their clinical importance ranges from mild conditions like pharyngitis to severe, life-threatening syndromes such as necrotizing fasciitis and toxic shock.

Description and classification

Streptococci are facultative anaerobes that typically appear in pairs or chains under microscopic examination, a morphology first described by the surgeon Theodor Billroth. They are catalase-negative, a key characteristic that differentiates them from the similar genus Staphylococcus. The primary classification system, developed by Rebecca Lancefield, is based on serological reactivity of the cell wall's C carbohydrate antigen, identifying groups such as Group A and Group B. In clinical laboratories, hemolysis patterns on blood agar plates—alpha-hemolysis, beta-hemolysis, and gamma-hemolysis—provide another critical taxonomic tool. Important species include the beta-hemolytic Streptococcus pyogenes and Streptococcus agalactiae, and the alpha-hemolytic Streptococcus pneumoniae and viridans group streptococci like Streptococcus mutans.

Pathogenesis and virulence factors

The pathogenicity of streptococci is mediated by a diverse arsenal of surface components and secreted toxins. Key virulence factors include the anti-phagocytic M protein, a primary target for typing by the Centers for Disease Control and Prevention, and the hyaluronic acid capsule. Enzymes such as streptolysin O, streptolysin S, and streptokinase facilitate tissue invasion and dissemination. Pyrogenic exotoxins, formerly known as erythrogenic toxin, are superantigens that can trigger severe immune responses, leading to conditions like scarlet fever and streptococcal toxic shock syndrome. The ability to form biofilms, particularly by species like Streptococcus mutans in dental plaque, is another critical pathogenic mechanism.

Common infections and diseases

Streptococci cause a broad array of infections, often categorized by the responsible species. Streptococcus pyogenes (Group A) is the etiological agent for strep throat, impetigo, and cellulitis, and can lead to the post-infectious sequelae of acute rheumatic fever and post-streptococcal glomerulonephritis. Invasive diseases include necrotizing fasciitis and puerperal fever. Streptococcus agalactiae (Group B) is a leading cause of neonatal sepsis and meningitis. Streptococcus pneumoniae is a major cause of community-acquired pneumonia, otitis media, and bacterial meningitis. Viridans group streptococci are implicated in dental caries and infective endocarditis.

Diagnosis and identification

Accurate diagnosis relies on a combination of clinical assessment and laboratory techniques. Initial identification often involves culturing specimens on blood agar to observe characteristic hemolysis and colony morphology. The CAMP test is a specific method for presumptively identifying Streptococcus agalactiae. Serological grouping using Lancefield grouping reagents remains a standard practice. Rapid antigen detection tests, such as those for Group A streptococcus pharyngitis, provide quick results in clinical settings. For definitive species identification, especially for non-groupable or alpha-hemolytic strains, automated systems like the VITEK or MALDI-TOF mass spectrometry are employed. Molecular methods, including polymerase chain reaction assays, are increasingly used for direct detection from clinical samples.

Treatment and antibiotic resistance

The cornerstone of treatment for most streptococcal infections is prompt antibiotic therapy. Penicillin remains the drug of choice for infections caused by Streptococcus pyogenes and Streptococcus agalactiae, with ampicillin and ceftriaxone as common alternatives. For penicillin-allergic patients, erythromycin or clindamycin may be used. However, resistance to macrolide antibiotics is a growing concern in regions like Europe and Asia. Streptococcus pneumoniae exhibits more significant resistance patterns, including penicillin-non-susceptible strains, often necessitating treatment with higher-generation cephalosporins or vancomycin for invasive disease. Ongoing surveillance by organizations like the World Health Organization monitors these resistance trends globally.

Prevention and control

Preventive strategies are crucial for mitigating the burden of streptococcal disease. For Streptococcus pneumoniae, widespread vaccination with the pneumococcal conjugate vaccine and the pneumococcal polysaccharide vaccine has dramatically reduced the incidence of invasive disease. Intrapartum antibiotic prophylaxis with penicillin or ampicillin is standard in many countries to prevent early-onset disease caused by Streptococcus agalactiae. Infection control measures, including proper hand hygiene and the management of outbreaks in settings like long-term care facilities, are essential. Research into vaccines targeting Streptococcus pyogenes, such as those based on the M protein, is an active area of investigation by institutions like the National Institutes of Health.

Category:Streptococcaceae Category:Bacterial genera